alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › linagliptin

linagliptin

6 studies tagged linagliptin, dated 2019-05-08 to 2023-07-27. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Neuroprotective Impact of Linagliptin against Cadmium-Induced Cognitive Impairment and Neuropathological Aberrations: Targeting SIRT1/Nrf2 Axis, Apoptosis, and Autophagy 2023-07-27
  2. Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease 2023-04-20
  3. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease 2021-06-11

Studies

6 studies carry this tag.

Date range

2019 to 2023

Top journals

  • International journal of molecular sciences 2
  • Frontiers in neurology 1
  • Neurochemical research 1
  • Neuropharmacology 1
  • Pharmaceuticals (Basel, Switzerland) 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Neuroprotective Impact of Linagliptin against Cadmium-Induced Cognitive Impairment and Neuropathological Aberrations: Targeting SIRT1/Nrf2 Axis, Apoptosis, and Autophagy

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceuticals (Basel, Switzerland) 2023-07-27 Drug development

    Cadmium is an environmental contaminant associated with marked neurotoxicity and cognitive impairment.

  2. Neuroprotective Role of DPP-4 Inhibitor Linagliptin Against Neurodegeneration, Neuronal Insulin Resistance and Neuroinflammation Induced by Intracerebroventricular Streptozotocin in Rat Model of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurochemical research 2023-04-20 Drug development

    Alzheimer's disease (AD) is an age-related, multifactorial progressive neurodegenerative disorder manifested by cognitive impairment and neuronal death in the brain areas like hippocampus, yet the precise neuropathology of AD is still unclear.

  3. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuropharmacology 2021-06-11 Drug development

    Alzheimer's disease (AD) is the most devastating neurodegenerative disorder, accounting over 46 million cases of dementia globally.

  4. Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2019-08-20 Drug development

    Linagliptin is a representative of dipeptidyl peptidase 4 (DPP-4) inhibitors which are registered and used effectively in a treatment of diabetes mellitus type 2.

  5. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2019-05-23 Drug development

    Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer's disease.

  6. Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in neurology 2019-05-08 Drug development

    Cerebral stroke is a leading cause of death and persistent disability of elderly in the world.

All topic tags with their study counts